| Literature DB >> 30413513 |
Christianne T van Lieshout1, Joeri K Tijdink2, Yvo M Smulders1.
Abstract
OBJECTIVES: To assess the duration of display of conflict of interest (COI) disclosure slides of presentations at the European Society of Cardiology (ESC) Congress 2016, and to identify factors associated with the duration of display of the disclosure slide.Entities:
Keywords: ethics (see medical ethics); internal medicine; medical ethics
Mesh:
Year: 2018 PMID: 30413513 PMCID: PMC6231600 DOI: 10.1136/bmjopen-2018-023534
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Flowchart of study inclusion. ESC, European Society of Cardiology.
Figure 2Duration of display of the conflict of interest disclosure slide in relation to the number of disclosures.
Presentation characteristics and univariate analyses of associations with disclosure time
| Characteristics | COI display duration | Duration per disclosure | ||||||||
| N | Median | IQR | Sig* | N | Median | IQR | Sig* | |||
| Gender | ||||||||||
| Male | 1322 | 2.60 | 1.52 | 4.29 | 0.000 | 622 | 0.72 | 0.30 | 1.76 | 0.000 |
| Female | 351 | 2.20 | 1.30 | 3.47 | 84 | 1.31 | 0.51 | 6.92 | ||
| Estimated age† | ||||||||||
| 15–25 | 5 | 1.98 | 1.48 | 6.71 | 0.000 | 1 | – | – | – | 0.000 |
| 25–35 | 213 | 2.38 | 1.52 | 3.45 | 37 | 2.34 | 0.95 | 4.44 | ||
| 35–45 | 325 | 2.56 | 1.48 | 6.59 | 92 | 1.02 | 0.30 | 2.31 | ||
| 45–55 | 367 | 2.46 | 1.31 | 4.24 | 158 | 0.70 | 0.32 | 2.41 | ||
| 55–65 | 619 | 2.51 | 1.52 | 4.29 | 331 | 0.69 | 0.30 | 1.51 | ||
| 65–75 | 129 | 2.96 | 1.67 | 6.30 | 78 | 0.69 | 0.27 | 1.66 | ||
| 75–85 | 14 | 5.00 | 1.42 | 16.64 | 9 | 1.02 | 0.65 | 2.67 | ||
| Region of location of the speaker’s institution | ||||||||||
| Northern Europe | 294 | 3.06 | 1.68 | 4.92 | 0.000 | 138 | 1.20 | 0.63 | 3.16 | 0.000 |
| Eastern Europe | 74 | 2.04 | 1.26 | 3.27 | 27 | 0.55 | 0.14 | 0.99 | ||
| Southern Europe | 356 | 1.89 | 1.27 | 3.37 | 101 | 0.58 | 0.26 | 1.32 | ||
| Western Europe | 544 | 2.59 | 1.53 | 4.18 | 269 | 0.62 | 0.28 | 1.63 | ||
| USA+Canada | 208 | 3.43 | 1.91 | 6.27 | 136 | 0.86 | 0.38 | 2.71 | ||
| Central+South America | 19 | 2.49 | 1.58 | 3.81 | 4 | 2.52 | 0.70 | 3.07 | ||
| Africa+East Asia | 36 | 1.62 | 0.92 | 2.54 | 5 | 0.98 | 0.16 | 4.76 | ||
| Asia | 119 | 2.35 | 1.52 | 3.45 | 18 | 1.37 | 0.41 | 2.34 | ||
| Australia+New Zealand | 23 | 2.33 | 1.17 | 2.77 | 8 | 0.57 | 0.32 | 5.57 | ||
| Subject type † | ||||||||||
| Guideline | 90 | 2.07 | 1.28 | 3.31 | 0.039 | 46 | 0.38 | 0.17 | 1.50 | 0.000 |
| Overview | 576 | 2.66 | 1.48 | 4.48 | 323 | 0.65 | 0.29 | 1.50 | ||
| Observational study | 390 | 2.65 | 1.61 | 3.85 | 102 | 1.73 | 0.60 | 4.11 | ||
| Experimental study | 161 | 2.85 | 1.87 | 4.01 | 70 | 0.91 | 0.38 | 2.55 | ||
| Case report | 179 | 2.13 | 1.35 | 3.36 | 61 | 0.77 | 0.29 | 1.39 | ||
| Informative talk | 255 | 2.19 | 1.29 | 4.49 | 102 | 0.85 | 0.33 | 1.93 | ||
| Systematic review | 21 | 3.71 | 2.16 | 4.85 | 2 | 3.86 | 2.12 | – | ||
| Subject of presentation‡ | ||||||||||
| Commercial relevance | 425 | 3.26 | 1.97 | 5.09 | 0.000 | 281 | 0.72 | 0.33 | 4.82 | 0.831 |
| No commercial relevance | 1246 | 2.26 | 1.36 | 3.78 | 425 | 0.79 | 0.30 | 1.92 | ||
| Disclosures also presented on title slide | ||||||||||
| No | 1618 | 2.54 | 1.49 | 4.15 | 0.000 | 687 | 0.79 | 0.32 | 1.96 | 0.031 |
| Yes | 55 | 1.64 | 1.01 | 2.30 | 19 | 0.42 | 0.26 | 0.88 | ||
| Disclosures present† | ||||||||||
| Absent | 948 | 2.00 | 1.27 | 3.20 | 0.000 | – | – | – | – | – |
| Present (median # is 5) | 724 | 3.44 | 2.00 | 6.27 | 706 | 0.78 | 0.32 | 1.94 | ||
| Verbal disclosure§ | ||||||||||
| No | 536 | 1.31 | 0.93 | 1.86 | 0.000 | 175 | 0.39 | 0.22 | 0.97 | 0.000 |
| Yes, ‘present’ | 1000 | 2.99 | 2.06 | 4.51 | 407 | 0.72 | 0.33 | 1.65 | ||
| Yes, partially specified | 102 | 11.11 | 6.58 | 15.54 | 90 | 1.75 | 0.81 | 4.10 | ||
| Yes, complete | 35 | 7.84 | 5.31 | 11.30 | 34 | 6.33 | 4.10 | 9.02 | ||
| Commerciality of COI¶ | ||||||||||
| Commercial COI | 599 | 3.24 | 1.93 | 5.41 | 0.000 | 594 | 0.79 | 0.33 | 1.97 | 0.000 |
| Non-commercial COI | 29 | 4.80 | 2.63 | 14.34 | 29 | 3.67 | 1.85 | 10.26 | ||
| Both | 86 | 4.57 | 2.26 | 8.71 | 79 | 0.42 | 0.19 | 0.92 | ||
| Type of COI** | ||||||||||
| Personal | 111 | 3.07 | 2.02 | 5.31 | 0.600 | 107 | 1.65 | 0.44 | 3.13 | 0.000 |
| Consultancy | 108 | 3.21 | 1.85 | 4.88 | 108 | 1.23 | 0.61 | 3.21 | ||
| Research | 120 | 3.64 | 2.11 | 7.15 | 114 | 1.57 | 0.82 | 3.42 | ||
| Any combination | 378 | 3.51 | 1.96 | 5.27 | 367 | 0.49 | 0.25 | 0.99 | ||
*Significance level is the p value of the logarithmically transformed COI display duration.
†One missing value.
‡Two missing values.
§Presence of verbal disclosure is subdivided in no verbal disclosure; solely mentioning the presence or absence of disclosures; a partial specification of the disclosed COI (eg, ‘research funding’); or a complete verbal disclosure (eg, including pharmaceutical company names).
¶Commercial COIs are that with pharmaceutical or device companies; non-commercial disclosures are that with government funding or public funding.
**Personal disclosures are eg, lecture fees and travel support, consultancy disclosures include royalties, ownership and stockholdership.
COI, conflict of interest.
Figure 3Regions of location of the speaker’s institution, based on the United Nations geographic regions.9
Figure 4Forest plot of the multiple linear regression with disclosure time as dependent variable. COI, conflict of interest.